Players: Thermo Fisher, Merck KGaA, Danaher, Agilent and QIAGEN. Profile covers CRISPR screening segments, trends, competition, regions and opportunities.
Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Pooled Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Global Market Report 2026" has been added to ResearchAndMarkets.com'soffering.
The global pooled clustered regularly interspaced short palindromic repeats (CRISPR) screening market is experiencing rapid growth, supported by expanding functional genomics research, pharmaceutical research and development, and advances in gene-editing technologies. The market is projected to increase from $1.3 billion in 2025 to $1.51 billion in 2026, representing a compound annual growth rate (CAGR) of 15.9%. Historical growth has been driven by the rising adoption of CRISPR-Cas9 technology, improvements in gene-editing tools, increased pharmaceutical research activity, and the expansion of academic genomics programs.
Strong momentum is expected to continue through 2030, when the pooled CRISPR screening market is forecast to reach $2.74 billion at a CAGR of 16.1%. Key growth factors include artificial intelligence-enabled gene screening, cloud-based genomics platforms, personalized medicine applications, biotechnology infrastructure expansion, and greater automation of high-throughput screening workflows. Leading market trends include integration with multi-omics data, automated CRISPR processes, AI-driven gene target identification, and real-time functional genomics analysis.
The increasing prevalence and detection of genetic disorders is a major factor supporting pooled CRISPR screening market growth. Advanced parental age, broader access to genetic screening, and improved diagnostic capabilities are contributing to higher identification and reporting rates. Pooled CRISPR screening enables researchers to conduct genome-wide studies that identify disease-associated genes, regulatory pathways, and potential therapeutic targets. In October 2024, the Cystic Fibrosis Trust reported that the number of registered cystic fibrosis patients in the UK increased from approximately 11,148 in 2022 to 11,318 in 2023, reflecting year-over-year growth of about 1.5%.
Innovation in transcriptome-wide profiling is also strengthening the market by enabling high-throughput functional genomics and more precise therapeutic target identification. In June 2023, Parse Biosciences Inc. launched CRISPR Detect, a technology designed for high-scale, single-cell pooled CRISPR screening. Integrated with the company's Evercode Whole Transcriptome platform, the solution pairs individual gene perturbations with whole-transcriptome expression profiles across as many as one million cells per experiment. This approach addresses throughput and cost limitations associated with droplet-based single-cell RNA sequencing while broadening opportunities in genome-scale gene function analysis, regulatory network mapping, signaling pathway research, and drug discovery.
Rising research and development investment is further accelerating adoption of pooled CRISPR screening technologies. Increased funding allows biotechnology companies, pharmaceutical developers, and research institutions to improve gene-editing tools, optimize experimental protocols, enhance screening accuracy, and shorten the time required to identify gene functions and potential drug targets. According to the UK Office for National Statistics, UK government net spending on research and development rose by 8.2%, from £16.1 billion ($20.45 billion) in 2022 to £17.4 billion ($22.1 billion) in 2023. Continued public and private investment is expected to support wider deployment of advanced CRISPR screening platforms.
The market includes genome-wide and targeted screening solutions, as well as libraries, reagents and kits, instruments, software, and services. Core technologies include CRISPR-Cas9 screening, CRISPR interference screening, and CRISPR activation screening. Major applications span functional genomics, drug discovery, cancer research, and gene regulation. Demand comes primarily from pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations seeking scalable tools for disease modeling and therapeutic development.
North America was the largest regional market for pooled CRISPR screening in 2025, supported by established biotechnology infrastructure, substantial research funding, and strong adoption of advanced genomics technologies. Asia-Pacific is expected to be the fastest-growing region during the forecast period as investment in biotechnology, pharmaceutical research, and precision medicine increases. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries assessed include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the UK, the USA, Canada, Italy, and Spain.
Markets Covered:
1) By Screening Type: Genome Wide Screening; Targeted Screening
2) By Product Type: Libraries; Reagents and Kits; Instruments; Software; Services
3) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Cas9 Screening; Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Interference Screening; Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Activation Screening
4) By Application: Functional Genomics; Drug Discovery; Cancer Research; Gene Regulation; Other Applications
5) By End-User: Pharmaceutical and Biotechnology Companies; Academic and Research Institutes; Contract Research Organizations; Other End-Users
Subsegments:
1) By Genome Wide Screening: Knockout Screening; Activation Screening; Interference Screening
2) By Targeted Screening: Gene Specific Knockout; Gene Specific Activation; Gene Specific Interference
Time Series:
Five years historic and ten years forecast.
Data:
Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation:
Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
| Report Attribute |
Details |
|---|---|
| No. of Pages |
250 |
| Forecast Period |
2026 - 2030 |
| Estimated Market Value (USD) in 2026 |
$1.51 Billion |
| Forecasted Market Value (USD) by 2030 |
$2.74 Billion |
| Compound Annual Growth Rate |
16.1% |
| Regions Covered |
Global |
Companies Featured
The companies featured in this Pooled Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening market report include:
-
Thermo Fisher Scientific Inc.
-
Merck KGaA
-
Danaher Corporation
-
Applied Biological Materials Inc.
-
Agilent Technologies Inc.
-
Charles River Laboratories International Inc.
-
QIAGEN N.V.
-
GenScript Biotech Corporation
-
Twist Bioscience Corporation
-
Ginkgo Bioworks Inc.
-
Element Biosciences Inc.
-
Synthego Corporation
-
Bit.bio Limited
-
Bioneer Corporation
-
VectorBuilder Inc.
-
Admera Health LLC
-
Addgene Inc.
-
Creative Biogene Inc.
-
Cellecta Inc.
-
Vivlion Inc.
-
GeneCopoeia Inc.
For more information about this report visit https://www.researchandmarkets.com/r/hd5mi1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
